Mizoribine, tacrolimus, and corticosteroid combination therapy successfully induces remission in patients with lupus nephritis

Clinical and Experimental Nephrology

Volumn 16, Issue 5, 2012, Pages 760-766

  Kagawa, Hidetoshi ^a   Hiromasa, Tsutomu ^a   Hara, Takayuki ^a   Takaki, Ayako ^a   Yamanaka, Ryutaro ^a   Sada, Ken Ei ^b   Makino, Hirofumi ^b  

^a HIMEJI RED CROSS HOSPITAL   (Japan)

^b OKAYAMA UNIVERSITY   (Japan)

Author keywords

Induction therapy; Lupus nephritis; Mizoribine; Multitarget therapy; Systemic lupus erythematosus; Tacrolimus

Indexed keywords

COMPLEMENT COMPONENT C3; CORTICOSTEROID; CREATININE; DOUBLE STRANDED DNA ANTIBODY; HEMOGLOBIN; METHYLPREDNISOLONE; MIZORIBINE; PREDNISOLONE; SERUM ALBUMIN; TACROLIMUS;

ADULT; AGED; ALBUMIN BLOOD LEVEL; ANTIBODY TITER; ARTICLE; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; COMPLEMENT BLOOD LEVEL; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSLIPIDEMIA; FEMALE; GLOMERULUS FILTRATION RATE; HERPES ZOSTER; HUMAN; HYPERTENSION; LUPUS ERYTHEMATOSUS NEPHRITIS; NEPHROTIC SYNDROME; PILOT STUDY; PROTEINURIA; REMISSION; RETROSPECTIVE STUDY; SCORING SYSTEM; SIDE EFFECT; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC LUPUS ERYTHEMATOSUS DISEASE ACTIVITY INDEX;

ADRENAL CORTEX HORMONES; ADULT; AGED; CREATININE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUPUS ERYTHEMATOSUS, SYSTEMIC; LUPUS NEPHRITIS; METHYLPREDNISOLONE; MIDDLE AGED; PILOT PROJECTS; PREDNISOLONE; PROTEINURIA; REMISSION INDUCTION; RETROSPECTIVE STUDIES; RIBONUCLEOSIDES; TACROLIMUS; TREATMENT OUTCOME;

EID: 84868341538     PISSN: 13421751     EISSN: 14377799     Source Type: Journal    
DOI: 10.1007/s10157-012-0632-4     Document Type: Article

References (36)

1. Moss KE, Ioannou Y, Sultan SM, Haq I, Isenberg DA. Outcome of a cohort of 300 patients with systemic lupus erythematosus attending a dedicated clinic for over two decades. Ann Rheum Dis. 2002;61:409-13.
2. Manger K, Manger B, Repp R, Geisselbrecht M, Geiger A, Pfahlberg A, et al. Definition of risk factors for death, end stage renal disease, and thromboembolic events in a monocentric cohort of 338 patients with systemic lupus erythematosus. Ann Rheum Dis. 2002;61:1065-70.
3. Bernatsky S, Boivin JF, Joseph L, Manzi S, Ginzler E, Gladman DD, et al. Mortality in systemic lupus erythematosus. Arthritis Rheum. 2006;54:2550-7.
4. Kon T, Yamaji K, Sugimoto K, Ogasawara M, Kenpe K, Ogasawara H, et al. Investigation of pathological and clinical features of lupus nephritis in 73 autopsied cases with systemic lupus erythematosus. Mod Rheumatol. 2009;20:168-77.
5. Chen YE, Kobert SM, Katz RS, Schwartz MM, Collaborative Study Group. Value of a complete or partial remission in severe lupus nephritis. Clin J Am Soc Nephrol. 2008;3:46-53.
6. Houssiau FA, Vasconcelos C, D'Cruz D, Sebastiani GD, de Ramon Garrido E, Danieli MG, et al. Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis: lessons from long-term followup of patients in the Euro-Lupus Nephritis Trial. Arthritis Rheum. 2004;50:3934-40.
7. Houssiau FA, Vasconcelos C, D'Cruz D, Sebastiani GD, de Ramon Garrido E, Danieli MG, et al. The 10-year follow-up data of the Euro-Lupus Nephritis Trial comparing low-dose and highdose intravenous cyclophosphamide. Ann Rheum Dis. 2010;69: 61-4.
8. Gourley MF, Austin HA 3rd, Scott D, Yarboro CH, Vaughan EM, Muir J, et al. Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis. Ann Intern Med. 1996;125:549-57.
9. Korbet SM, Lewis EJ, Schwartz MM, Reichlin M, Evans J, Rohde RD. Factors predictive of outcome in severe lupus nephritis. Am J Kidney Dis. 2000;35:904-14.
10. Ioannidis JPA, Boki KA, Katsorida EM, Drosos AA, Skopouli FN, Boletis JN. Remission, relapse, and re-remission of proliferative lupus nephritis treated with cyclophosphamide. Kidney Int. 2000;57:258-64.
11. Illei GG, Austin HA, Crane M, Collins L, Gourley MF, Yarboro CH, et al. Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis. Ann Intern Med. 2001;135:248-57.
12. Mok CC, Ying KY, Tang S, Leung CY, Lee KW, Ng WL, et al. Predictors and outcome of renal flares after successful cyclophosphamide treatment for diffuse proliferative lupus glomerulonephritis. Arthritis Rheum. 2004;50:2559-68.
13. Waldman M, Appel GB. Update on the treatment of lupus nephritis. Kidney Int. 2006;70:1403-12.
14. Appel GB, Contreras G, Dooley MA, Ginzler EM, Isenberg D, Jayne D, et al. Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol. 2009;20:1103-12.
15. Boumpas DT, Austin HA 3rd, Fessler BJ, Balow JE, Klippel JH, Lockshin MD, et al. Systemic lupus erythematosus: emerging concepts. Part I. Renal, neuropsychiatric, cardiovascular, pulmonary, and hematologic disease. Ann Intern Med. 1995;122:940-50.
16. Kawasaki Y. Mizoribine: a new approach in the treatment of renal disease. Clin Dev Immunol. 2009;2009:681482.
17. Kasama T, Wakabayashi K, Odai T, Isozaki T, Matsunawa M, Yajima N, et al. Effects of low-dose mizoribine pulse therapy in combination with methotrexate in rheumatoid arthritis patients with an insufficient response to methotrexate. Mod Rheumatol. 2009;19:395-400.
18. Horikoshi M, Ito S, Ishikawa M, Umeda N, Kondo Y, Tsuboi H, et al. Efficacy of mizoribine pulse therapy in patients with rheumatoid arthritis who show a reduced or insufficient response to infliximab. Mod Rheumatol. 2009;19:229-34.
19. Yumura W, Suganuma S, Uchida K, Moriyama T, Otsubo S, Takei T, et al. Effects of long-term treatment with mizoribine in patients with proliferative lupus nephritis. Clin Nephrol. 2005;64:28-34.
20. Kuroda T, Hirose S, Tanabe N, Sato H, Nakatsue T, Ajiro J, et al. Mizoribine therapy for patients with lupus nephritis: the association between peak mizoribine concentration and clinical efficacy. Mod Rheumatol. 2007;17:206-12.
21. Tanaka H, Tsugawa K, Oki E, Suzuki K, Ito E. Mizoribine intermittent pulse protocol for induction therapy for systemic lupus erythematosus in children: an open-label pilot study with five newly diagnosed patients. Clin Rheumatol. 2008;27:85-9.
22. Tanaka H, Oki E, Tsuruga K, Sato N, Matsukura A, Kondo Y, et al. Mizoribine treatment of young patients with severe lupus nephritis: a clinicopathologic study by the Tohoku pediatric study group. Nephron Clin Pract. 2008;110(2):c739.
23. Mok CC, Tong KH, To CH, Siu YP, Au TC. Tacrolimus for induction therapy of diffuse proliferative lupus nephritis: an open-labeled pilot study. Kidney Int. 2005;68:813-7.
24. Maruyama M, Yamasaki Y, Sada KE, Sarai A, Ujike K, Maeshima Y, et al. Good response of membranous lupus nephritis to tacrolimus. Clin Nephrol. 2006;65:276-9.
25. Szeto CC, Kwan BC, Lai FM, Tam LS, Li EK, Chow KM, et al. Tacrolimus for the treatment of systemic lupus erythematosus with pure class V nephritis. Rheumatology. 2008;47:1678-81.
26. Miyasaka N, Kawai S, Hashimoto H. Efficacy and safety of tacrolimus for lupus nephritis: a placebo-controlled double-blind multicenter study. Mod Rheumatol. 2009;19:606-15.
27. Kusunoki Y, Tanaka N, Kaneko K, Yamamoto T, Endo H, Kawai S. Tacrolimus therapy for systemic lupus erythematosus without renal involvement: a preliminary retrospective study. Mod Rheumatol. 2009;19:616-21.
28. Lee T, Oh KH, Joo KW, Kim YS, Ahn C, Han JS, et al. Tacrolimus is an alternative therapeutic option for the treatment of refractory lupus nephritis. Lupus. 2010;19:974-80.
29. Chen W, Tang X, Liu Q, Chen W, Fu P, Liu F, et al. Short-term outcomes of induction therapy with tacrolimus versus cyclophosphamide for active lupus nephritis: a multicenter randomized clinical trial. Am J Kidney Dis. 2011;57:235-44.
30. Takahashi S, Hiromura K, Sakurai N, Matsumoto T, Ikeuchi H, Maeshima A, et al. Efficacy and safety of tacrolimus for induction therapy in patients with active lupus nephritis. Mod Rheumatol. 2011;21:282-9.
31. Lee YH, Lee HS, Choi SJ, Dai Ji J, Song GG. Efficacy and safety of tacrolimus therapy for lupus nephritis: a systematic review of clinical trials. Lupus. 2011;20:636-40.
32. Morita Y, Sasae Y, Sakuta T, Satoh M, Sasaki T, Kashihara N. Efficacy of low-dose tacrolimus added to methotrexate in patients with rheumatoid arthritis in Japan: a retrospective study. Mod Rheumatol. 2008;18:379-84.
33. Bao H, Liu ZH, Xie HL, Hu WX, Zhang HT, Li LS. Successful treatment of class V?IV lupus nephritis with multitarget therapy. J Am Soc Nephrol. 2008;19:2001-10.
34. Sonda K, Takahashi K, Tanabe K, Funchinose S, Hayasaka Y, Kawaguchi H, et al. Clinical pharmacokinetic study of mizoribine in renal transplantation patients. Transplant Proc. 1996;28: 3643-8.
35. Gladmann DD, Ibanez D, Urowitz MZ. Systemic lupus erythematosus disease activity index 2000. J Rheumatol. 2002;29: 288-91.
36. Houssiau F. Thirty years of cyclophosphamide: assessing the evidence. Lupus. 2007;16:212-6.